Impact of Risperidone in the treatment of fecal incontinence among children

Comparison of the effect of Risperidone and placebo in the treatment of fecal incontinence in children 4 -18 years of age suffering from functional constipation and fecal incontinence, with and without neuropsychiatric disorders

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200203046352N1

Enrollment

140

Registered

2022-06-19

Start date

2020-01-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional constipation, Fecal incontinence, NDD.

Interventions

Intervention 1: Intervention group: 34 patients with functional constipation and fecal incontinence who receive a daily dose of 0.25-0.5 mg (every 12 hours) of risperidone syrup for 12 weeks. Interven

Eligibility

Sex/Gender

All

Age

4 Years to 18 Years

Inclusion criteria

Inclusion criteria: Functional constipation Fecal incontinence Age between 4 and 18 neuropsychiatric disorders in half of participants Absence of neuropsychiatric disorders in half of participants

Exclusion criteria

Exclusion criteria: Anatomical and hormonal causes of constipation Presence of other GI disorders

Design outcomes

Primary

Measure	Time frame
Fecal incontinence. Timepoint: every month for 6 months. Method of measurement: interview with parents.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghazaal Zaahed

Shahid Beheshti University of Medical Sciences

ghazal.zahed@gmail.com+98 21 2222 7021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026